免疫检查点阻断时代转移性黑色素瘤手术的作用

Treatment paradigms have shifted with the introduction of checkpoint inhibitors, facilitating less extensive surgical procedures in some scenarios. Resection and adjuvant therapy are key components in patients with locally advanced or limited metastatic disease. Alternately, these patient populations may benefit from peri-operative systemic therapy based on recent clinical trial data.

Resection is also integral to administering tumor infiltrating lymphocyte therapy in patients with treatment-refractory, unresectable melanoma. The role of surgery continues to evolve, and ranges the spectrum from resection with curative intent, to palliative interventions intended to effectively manage symptoms or disease-related complications.